NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company's pipeline includes NFL-101, a drug candidate for smoking cessation, currently under CESTO II Phase 2 study; NFL-101, a drug candidate for smoking cessation; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation. NFL Biosciences SA was incorporated in 2006 and is headquartered in Castelnau-le-Lez, France.
Frequently asked questions
What sector does NFL Biosciences SAS (ALNFL) operate in?
NFL Biosciences SAS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is NFL Biosciences SAS (ALNFL) current stock price?
As of the latest data, NFL Biosciences SAS stock price is €0.86, with a previous close of €0.86.
What is NFL Biosciences SAS (ALNFL) current market capitalization?
NFL Biosciences SAS market cap is approximately 10.89 million.
What is NFL Biosciences SAS (ALNFL) Earnings Per Share (EPS)?
The trailing EPS is -€0.26, and the forward EPS is -€1.04.
Does NFL Biosciences SAS (ALNFL) pay dividends?
No. NFL Biosciences SAS does not pay a dividend.
What is NFL Biosciences SAS (ALNFL) beta (volatility) score?
NFL Biosciences SAS has a beta of 1.149, meaning its volatility is roughly in line with the market.
